The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...

A RETROSPECTIVE study conducted by Mass General Brigham researchers has found that taking semaglutide before bariatric ...

Experts stress that obesity is a disease, not a lifestyle choice, and call for better access to pharmacological and surgical ...

Semaglutide wasn't approved for obesity at higher doses until 2021, and therefore maximum weight-loss doses were often not reached by patients, Sheu's group pointed out. Also, since the cohort was ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...